DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs
Dassault took a safety-data platform, Tempus took the diagnostics layer it already sold, Repligen took biopreservation tools. Three deals, no molecules.
DealPulse
DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line
Thirty four healthcare deals crossed the wire the week of July 13, 2026. Four of the five that matter paid cash for something that already works: an operating rare-disease pharmacy, an FDA-approved drug, a Phase 3 asset with Breakthrough.
DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B
DealFlow H1 2026 Review: M&A Rebounds as Upfront Deal Spending Doubles Synopulse · DealFlow · Healthcare & life sciences dealmaking · H1 2026 review M&A came back big, and wrote the cheque in cash M&A value rose 96% to $188 billion in the first half of 2026 and upfront payments jumped 72%, as acquirers paid … Read more